Combining taxanes with radiation for solid tumors

Choy, Hak

doi:10.1002/1097-0215(20000620)90:3<113::aid-ijc1>3.0.co;2-c

Cited by 23 publications

(13 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Docetaxel is a semi-synthetic taxane with promising single-agent activity in advanced oesophageal cancer 17 . In vitro studies have also demonstrated that docetaxel enhances radiosensitivity via inducing mitotic arrest and apoptosis in murine tumour cells 11 , 18 . Several studies have reported promising efficacy of docetaxel and cisplatin (the DP regimen) in oesophageal cancer 13 - 16 .…”

Section: Discussionmentioning

confidence: 99%

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma

Zhu¹,

Zhang²,

Li³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (CCRT) with docetaxel plus cisplatin (DP regimen) versus 5-fluorouracil plus cisplatin (PF regimen) in patients with oesophageal squamous cell carcinoma (ESCC). Patients and Methods: In this phase II randomized controlled trial, eighty-six patients with clinical stage II - IVa ESCC were randomized to receive radiotherapy concurrently with two cycles of the PF or DP regimen at 3-week intervals. The primary endpoint was overall survival (OS). The secondary end points included the overall response rate (ORR), progression-free survival (PFS) and treatment-related toxicities. Results: The ORRs were 84.4% in the DP group and 87.3% in the PF group (P = 0.653). After a median follow-up time of 25.1 months, the 1- and 2-year OS rates were 93.7% and 86.2% for the PF group and 87.3% and 69.1% for the DP group, respectively (P = 0.364). The 1- and 2-year PFS rates were 77.4% and 55.0% for the PF group and 78.8% and 69.4% for the DP group, respectively (P = 0.845). Grade 3/4 leukocytopenia/neutropenia (68.9% vs. 19.5%, P < 0.001) was significantly more common in the DP group. Conclusion: The treatment response, OS and PFS associated with using CCRT with the DP regimen were not superior to those associated with using CCRT with the PF regimen as a first-line treatment in patients with ESCC. Additionally, the DP regimen was associated with more severe haematological toxicities. This trial has been registered with the US National Institute of Health (clinicaltrials.gov, Identifier NCT 02969473).

show abstract

Section: Discussionmentioning

confidence: 99%

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma

Zhu¹,

Zhang²,

Li³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The chemotherapeutic paclitaxel has been identified in several studies to have radiosensitizing properties and has been combined with both external beam radiotherapy and radioimmunotherapy in several preclinical and clinical studies (24,29,48). A study by Supiot et al (23) has examined sensitisation to a-radioimmunotherapy using paclitaxel and doxorubicin, where paclitaxel was observed to enhance the efficacy of a-radioimmunotherapy of myeloma cell lines through mediating cell cycle arrest and increasing DNA strand breaks, providing a solid rationale for the investigation of combining a-particle radioimmunotherapy with chemotherapies.…”

Section: Discussionmentioning

confidence: 99%

Radioimmunotherapy with α-Particle–Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy

Kelly

Lee

Tahtis

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Previous experience in solid tumor radioimmunotherapy studies has indicated that greatest therapeutic efficacy is achieved in the treatment of small-volume disease. a-Particleê mitting radioisotopes possess several physical characteristics ideally suited to the treatment of minimal residual disease. Therefore, we have investigated the efficacy of the a-particle^emitting bismuth-213 ( Bi-hu3S193 causes specific and significant retardation of tumor growth even in established tumors, and efficacy was enhanced by paclitaxel to produce defined complete responses. Conclusions: These studies show the potency of a-particle radioimmunotherapy and warrant its further exploration in the treatment of micrometastatic disease in Le y -positive malignancies.

show abstract

“…These drugs are registered for and used in the treatment of a variety of cancers, such as ovarian, breast, prostate, and non-small cell lung cancer (12). There is a large interindividual variability in the pharmacokinetics of taxanes, their toxicity, and therapeutic response (13,14).…”

Section: Introductionmentioning

confidence: 99%

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

Graan

Loos

Friberg

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Cigarette smoke is known to interact with the metabolism of several anticancer drugs. It may also affect the incidence and severity of adverse events and efficacy of chemotherapy. The main objective of this study was to examine the effects of smoking on the pharmacokinetics and toxicities of patients treated with docetaxel or paclitaxel.Experimental Design: Smoking status, toxicity profiles, and pharmacokinetic parameters (calculated by nonlinear mixed-effect modeling population analysis) were determined in 566 patients (429 nonsmokers and 137 smokers) treated with docetaxel or paclitaxel.Results: Smokers treated with docetaxel showed less grade IV neutropenia (35% vs. 52%; P ¼ 0.01) than nonsmokers. Smokers treated with paclitaxel had less grade III-IV leukopenia than nonsmokers (12% vs. 25%; P ¼ 0.03), and the white blood cell (WBC) nadir was lower in nonsmokers (median, 2.7 Â 10 9 /L; range, 0.05 Â 10 9 to 11.6 Â 10 9 /L) than in smokers (median, 3.3 Â 10 9 /L; range 0.8 Â 10 9 to 10.2 Â 10 9 /L; P ¼ 0.02). Of interest, significantly lower WBC counts and absolute neutrophil counts at baseline were seen in nonsmoking patients treated with paclitaxel (P ¼ 0.0001). Pharmacokinetic parameters were similar in smokers and nonsmokers for both taxanes.Conclusion: Cigarette smoking does not alter the pharmacokinetic determinants of docetaxel and paclitaxel. Smokers treated with docetaxel and paclitaxel have less neutropenia and leukopenia, but further research is warranted to elucidate this potential protective effect.

show abstract

Combining taxanes with radiation for solid tumors

Cited by 23 publications

References 80 publications

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma

Radioimmunotherapy with α-Particle–Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

Contact Info

Product

Resources

About